Starpharma (ASX:SPL) see revenue rise 142%

Company News

by Rachael Jones

Starpharma (ASX:SPL) report their revenue is up 142 per cent to $6.56 million.

The increase in revenue reflects the AstraZeneca $4.3 million development milestone.

The company still reported loss after tax is $14.7 million from the expense of all research and development expenditure and patenting costs associated with VivaGel® and DEP® programs.

Shares in Starpharma (ASX:SPL) are trading 5.6 per cent higher at $1.41.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.